MXPA00007878A - - Google Patents

Info

Publication number
MXPA00007878A
MXPA00007878A MXPA/A/2000/007878A MXPA00007878A MXPA00007878A MX PA00007878 A MXPA00007878 A MX PA00007878A MX PA00007878 A MXPA00007878 A MX PA00007878A MX PA00007878 A MXPA00007878 A MX PA00007878A
Authority
MX
Mexico
Prior art keywords
interleukin
herpes simplex
suspension
mineral
antigen
Prior art date
Application number
MXPA/A/2000/007878A
Other languages
English (en)
Spanish (es)
Original Assignee
Genetics Institute Inc
Filing date
Publication date
Application filed by Genetics Institute Inc filed Critical Genetics Institute Inc
Publication of MXPA00007878A publication Critical patent/MXPA00007878A/xx

Links

MXPA/A/2000/007878A 2000-08-11 MXPA00007878A (enExample)

Publications (1)

Publication Number Publication Date
MXPA00007878A true MXPA00007878A (enExample) 2002-03-26

Family

ID=

Similar Documents

Publication Publication Date Title
AU764036B2 (en) Vaccines comprising interleukin-12 and herpes simplex viral antigen
Morein et al. Current status and potential application of ISCOMs in veterinary medicine
Hu et al. Immunostimulating complexes (ISCOMs) for nasal vaccination
JP5230780B2 (ja) アジュバント混合製剤
XIN et al. Intranasal administration of human immunodeficiency virus type‐1 (HIV‐1) DNA vaccine with interleukin‐2 expression plasmid enhances cell‐mediated immunity against HIV‐1
Golovliov et al. Adjuvanticity of ISCOMs incorporating a T cell-reactive lipoprotein of the facultative intracellular pathogen Francisella tularensis
Clarke et al. Mucosal priming of T-lymphocyte responses to fed protein antigens using cholera toxin as an adjuvant
Villacres-Eriksson et al. IMMUNOMODULATION BYQUILLAJA SAPONARIAADJUVANT FORMULATIONS: IN VIVO STIMULATION OF INTERLEUKIN 12 AND ITS EFFECTS ON THE ANTIBODY RESPONSE
Hassan et al. Immune responses in mice induced by HSV-1 glycoproteins presented with ISCOMs or NISV delivery systems
Dotsika et al. Influence of Quillaja saponaria triterpenoid content on the immunomodulatory capacity of Epstein–Barr virus Iscoms
Fernando et al. Vaccine‐induced Th1‐type responses are dominant over Th2‐type responses in the short term whereas pre‐existing Th2 responses are dominant in the longer term
MXPA00007878A (enExample)
NZ250555A (en) Vaccine with enhanced immunogenicity by inclusion of a cytokine
KR20010040932A (ko) 인터루킨-12 및 호흡기 합포체 바이러스 항원을 포함하는백신
Yu et al. Synthetic innate defense regulator peptide combination using CpG ODN as a novel adjuvant induces long‑lasting and balanced immune responses
JP2010209080A (ja) 新規ワクチン接種
Villacres-Eriksson et al. Modulation of cytokine responses by iscoms and iscom-matrix
MXPA00007881A (en) Vaccines comprising interleukin-12 and respiratory syncytial viral antigens
HK1118465A (en) Adjuvancy and immune potentiating properties of natural products of onchocerca volvulus